Because hyperglycemia is one of the leading risk factors for ischemic cerebrovascular diseases [16], it provided a potential clinical use of GLP-1R agonists for the treatment of stroke in T2D patients or individuals at high risk to suffer from a stroke (e.g. pretreatment strategies). The gene discussed is GLP1R; the disease is stroke disorder.